Brain-Disabling Treatments in Psychiatry
Peter R. Breggin
Links auf reinlesen.de sind sogenannte Affiliate-Links. Wenn du auf so einen Affiliate-Link klickst und über diesen Link einkaufst, bekommt reinlesen.de von dem betreffenden Online-Shop oder Anbieter eine Provision. Für dich verändert sich der Preis nicht.
Naturwissenschaften, Medizin, Informatik, Technik / Medizin
From the author of Toxic Psychiatry and Talking Back to Prozac:
"Peter Breggin is the conscience of American psychiatry. Once more he updates us on the real evidence with respect to the safety and effectiveness of specific psychiatric medications and ECT. This information is needed by all mental health professionals, as well as patients and families."
In Brain Disabling Treatments in Psychiatry, renowned psychiatrist Peter R. Breggin, M.D., presents startling scientific research on the dangerous behavioral abnormalities and brain dysfunctions produced by the most widely used and newest psychiatric drugs such as Prozac, Paxil, Zoloft, Cymbalta, Effexor, Xanax, Ativan, Ritalin, Adderall, Concerta, Strattera, Risperdal, Zyprexa, Geodon, Abilify, lithium and Depakote.
Many of Breggin's earlier findings have improved clinical practice, led to legal victories against drug companies, and resulted in FDA-mandated changes in what the manufacturers must admit about their drugs. Yet reliance on these drugs has continued to escalate in the last decade, and drug company interests have overwhelmed psychiatric practice.
This greatly expanded second edition, supported by the latest evidence-based research, shows that psychiatric drugs achieve their primary or essential effect by causing brain dysfunction, and that they tend to do far more harm than good.
New scientific analyses in this completely updated edition include:
- Chapters covering every new antidepressant and stimulant drug
- Twenty new guidelines for how to conduct non-drug therapy
- A chapter describing how to safely withdraw from psychiatric drugs
- A discussion of "medication spellbinding," explaining how patients fail to appreciate their drug-induced mental dysfunctions
- Documentation of how the drug companies control research and the flow of information about psychiatric treatments